At Novugen, our purpose is to bring affordable medicine to the world. Novugen’s globally-minded strategy, synergistic approach and wealth of experience enable us to respond to the complex challenge of bringing hard-to-source and technology-intensive products to market while maintaining affordable pricing and rigorous quality assurance. As a technology leader, we create efficiency by integrating our total value chain. At Novugen, our science and business teams work together seamlessly to innovate new concepts and fresh ideas.

We are the only organization in ASEAN to have a full-fledged API development R&D center in Malaysia and the first to be vertically integrated in the ASEAN region – from API development to finished product sales.

Novugen Pharma (Malaysia) Sdn. Bhd. is a wholly-owned subsidiary company of a UAE based group with more than 25 years of experience in strategic healthcare businesses and development of world class healthcare facilities around the globe.


We aim to accelerate the launch of pharmaceuticals that lack robust generic alternatives due to their complexity.

Manufacturing excellence

We provide the first multi-product commercial manufacturing plant in Malaysia designed by international experts following strict regulatory requirements by authorities across the globe including USFDA, EMA, PIC/S and WHO.

Team of 200 professionals

We are an experienced, diversified team with over 50 scientists having global product development experience.

Commercialization edge

We provide a strong sales and marketing presence and experience in launching branded generics in the ASEAN and MENA regions supported by a robust distribution network.

World-class R&D

We have a world-class advanced R&D center spread across our 40,000 sq. ft. facility.

Novugen Pharma is the first

We are the first Malaysian company to have filed API DMF and ANDA for US product registration.

Forging alliances with integrity and transparency

We seek to create value through strategic partnerships with license-in, license-out and CMO partnership opportunities.

Strategically targeted portfolio
  • We specialize in complex, niche and technology-intensive products that meet strict global quality standards covering all major therapeutic areas.
  • Our pipeline includes 10 ANDAs for the US market, half of which are FTF/FTM opportunities.
  • We already have 30 products for registration in CTD.